Development of a chemiluminescence immunoassay for serum YB-1 and its clinical application as a potential diagnostic marker for hepatocellular carcinoma

Hepatitis Monthly

Volumn 13, Issue 7, 2013, Pages

  Pu, Li ^a   Jing, Shi ^a   Bianqin, Guo ^a   Ping, Liu ^a   Qindong, Liang ^a   Chenggui, Liu ^a   Feng, Cheng ^a   Wenbin, Kuang ^a   Qin, Wang ^a   Jinyu, Dong ^a   Qianfeng, Xia ^b   Yu, Liu ^c   Zhiguang, Tu ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

^b HAINAN MEDICAL UNIVERSITY   (China)

^c Chongqing Tumor Hospital   (China)

Author keywords

Carcinoma; Hepatocellular; Tumor marker; Y Box binding protein 1

Indexed keywords

ALPHA FETOPROTEIN; LUNG RESISTANCE PROTEIN; MONOCLONAL ANTIBODY; MULTIDRUG RESISTANCE PROTEIN 1; NOTCH3 RECEPTOR; POLYCLONAL ANTIBODY; Y BOX BINDING PROTEIN 1;

ADULT; AGED; ARTICLE; CHEMILUMINESCENCE IMMUNOASSAY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HEPATITIS B; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN EXPRESSION; PROTEIN PURIFICATION; RECEIVER OPERATING CHARACTERISTIC; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; UPREGULATION; WESTERN BLOTTING;

EID: 84880080403     PISSN: 1735143X     EISSN: 17353408     Source Type: Journal    
DOI: 10.5812/hepatmon.8918     Document Type: Article

References (44)

1. Diamandis EP, Hofman BR, Sturgeon CM. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for the Use of Tumor Markers. Clin Chem. 2008;54(11):1935-1939.
2. Bertino G, Ardiri A, Malaguarnera M, Malaguarnera G, Bertino N, Calvagno GS. Hepatocellualar carcinoma serum markers. Semin Oncol. 2012;39(4):410-433.
3. Shen Q, Fan J, Yang XR, Tan Y, Zhao W, Xu Y, et al. Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study. Lancet Oncol. 2012;13(8):817-826.
4. Kohno K, Izumi H, Uchiumi T, Ashizuka M, Kuwano M. The pleio-tropic functions of the Y-box-binding protein, YB-1. Bioessays. 2003;25(7):691-698.
5. En-Nia A, Yilmaz E, Klinge U, Lovett DH, Stefanidis I, Mertens PR. Transcription factor YB-1 mediates DNA polymerase alpha gene expression. J Biol Chem. 2005;280(9):7702-7711.
6. Wu J, Lee C, Yokom D, Jiang H, Cheang MC, Yorida E, et al. Disruption of the Y-box binding protein-1 results in suppression of the epidermal growth factor receptor and HER-2. Cancer Res. 2006;66(9):4872-4879.
7. Tay WL, Yip GW, Tan P Matsumoto K, Yeo R, Ng TP, et al. Y-Box-binding protein-1 is a promising predictive marker of radio resistance and chemoradioresistance in nasopharyngeal cancer. Mod Pathol. 2009;22(2):282-290.
8. Wachowiak R, Thieltges S, Rawnaq T, Kaif JT, Fiegel H, Metzger R, et al. Y-box binding protein-1 is a potential novel tumour marker for neuroblastoma. Anticancer Res. 2010;30(4) 1239-1242
9. Kuwano M, Oda Y, Izumi H, Yang SJ, Uchiumi T, Uchiumi T, et al.The role of nuclear Y-box binding protein 1 as a global marker in drug resistance. Mol Cancer Ther. 2004;3(11):1485-1492.
10. Bargou RC, Jurchott K, Wagener C, Bergmann S, Metzner S, Bommert K, et al. Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression. Nat Med. 1997;3(4):447-450.
11. Dhillon J, Astanehe A, Lee C, Fotovati A, Hu K, Dunn SE. The expression of activated Y-box binding protein-1 serine 102 mediates trastuzumab resistance in breast cancer cells by increasing CD44+ cells. Oncogene. 2010;29(47):6294-6300.
12. Janz M, Harbeck N, Dettmar P, Berger U, Schmidt A, Jurchott K, et al. Y-box factor YB-1 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, uPA and PAI-1. Int J Cancer. 2002;97(3):278-282.
13. Shibahara K, Sugio K, Osaki T, Uchiumi T, Maehara Y, Kohno K, et al. Nuclear expression of the Y-box binding protein, YB-1, as a novel marker of disease progression in non-small cell lung cancer. Clin Cancer Res. 2001;7(10):3151-3155.
14. Das S, Chattopadhyay R, Bhakat KK, Boldogh I, Kohno K, Prasad R, et al. Stimulation of NEIL2-mediated oxidized base excision repair via YB-1 interaction during oxidative stress. J Biol Chem. 2007;282(39):28474-28484.
15. Shiota M, Zoubeidi A, Kumano M, Beraldi E, Naito S, Nelson CC, et al. Clusterin is a critical downstream mediator of stress-induced YB-1 transactivation in prostate cancer. Mol Cancer Res. 2011;9(12):1755-1766.
16. Szczuraszek K, Halon A, Materna V, Mazur G, Wrobel T, Kulicz-kowski K, et al. Elevated YB-1 expression is a new unfavorable prognostic factor in non-Hodgkin's lymphomas. Anticancer Res. 2011;31(9):2963-2970.
17. Frye BC, Halfter S, Djudjaj S, Muehlenberg P, Weber S, Rafetseder U, et al. Y-box protein-1 is actively secreted through a non-classical pathway and acts as an extracellular mitogen. EMBO Rep. 2009;10(7):783-789.
18. Tacke F, Kanig N, En-Nia A, Kaehne T, Eberhardt CS, Shpacovitch V, et al. Y-box protein-1/p18 fragment identifes malignancies in patients with chronic liver disease. BMC Cancer. 2011;11:185.
19. Kuwano M, Uchiumi T, Hayakawa H, Ono M, Wada M, Izumi H, et al. The basic and clinical implications of ABC transporters, Y-box-binding protein-1 (YB-1) and angiogenesis-related factors in human malignancies. Cancer Sci. 2003;94(1):9
20. Graslund S, Nordlund P, Weigelt J, Hallberg BM, Bray J, Gile-adi O, et al. Protein production and purifcation. Nat Methods. 2008;5(2):135-146.
21. Norwood TH, Zeigler CJ, Martin GM. Dimethyl sulfoxide enhances polyethylene glycol-mediated somatic cell fusion. Somatic Cell Genet. 1976;2(3):263-270.
22. Powers DM. Interference Testing in Clinical Chemistry: Approved Guideline. 2002.
23. Tholen DW. Evaluation of the Linearity of Quantitative Measurement Procedures: A Statistical Approach, Approved Guideline. 2003.
24. Tholen DW. Evaluation of Precision Performance of Quantitative Measurement Methods: Approved Guideline. 2004.
25. Rafetseder U, Rauen T, Boor P, Ostendorf T, Hanssen L, Floege J, et al. Extracellular YB-1 blockade in experimental nephritis up-regulates Notch-3 receptor expression and signaling. Nephron Exp Nephrol. 2011;118(4):e100-108.
26. Rauen T, Rafetseder U, Frye BC, Djudjaj S, Muhlenberg PJ, Eitner F, et al. YB-1 acts as a ligand for Notch-3 receptors and modulates receptor activation. J Biol Chem. 2009;284(39):26928-26940.
27. Giovannini C, Gramantieri L, Chieco P, Minguzzi M, Lago F, Pia-netti S, et al. Selective ablation of Notch3 in HCC enhances doxo-rubicin's death promoting efect by a p53 dependent mechanism. J Hepatol. 2009;50(5):969-979.
28. Giovannini C, Lacchini M, Gramantieri L, Chieco P, Bolondi L. Notch3 intracellular domain accumulates in HepG2 cell line. Anticancer Res. 2006;26(3A):2123-2127.
29. Haruki N, Kawaguchi KS, Eichenberger S, Massion PP, Olson S, Gonzalez A, et al. Dominant-negative Notch3 receptor inhibits mitogen-activated protein kinase pathway and the growth of human lung cancers.Cancer Res. 2005;65(9):3555-3561.
30. Konishi J, Kawaguchi KS, Vo H, Haruki N, Gonzalez A, Carbone DP, et al Gamma- secretase inhibitor prevents Notch3 activation and reduces proliferation in human lung cancers. Cancer Res. 2007;67(17):8051-8057.
31. Serafin V, Persano L, Moserle L, Esposito G, Ghisi M, Curtarello M, et al. Notch3 signalling promotes tumour growth in colorectal cancer. J Pathol. 2011;224(4):448-460.
32. Bergmann S, Royer-Pokora B, Fietze E, Jurchott K, Hildebrandt B, Trost D, et al. YB-1 provokes breast cancer through the induction of chromosomal instability that emerges from mitotic failure and centrosome amplifcation. Cancer Res. 2005;65(10):4078-4087.
33. Gimenez-Bonafe P, Fedoruk MN, Whitmore TG, Akbari M, Ra JL, Ettinger S, et al. YB- 1 is upregulated during prostate cancer tumor progression and increases P-glycoprotein activity. Prostate. 2004;59(3):337-349.
34. Huang X, Ushijima K, Komai K, Takemoto Y, Motoshima S, Kamu-ra T, et al. Co-expression of Y box-binding protein-1 and P-glyco-protein as a prognostic marker for survival in epithelial ovarian cancer. Gynecol Oncol. 2004;93(2):287-291.
35. Oda Y, Sakamoto A, Shinohara N, Ohga T, Uchiumi T, Kohno K, et al. Nuclear expression of YB-1 protein correlates with P-gly-coprotein expression in human osteosarcoma. Clin Cancer Res. 1998;4(9):2273-2277.
36. Saji H, Toi M, Saji S, Koike M, Kohno K, Kuwano M. Nuclear expression of YB-1 protein correlates with P-glycoprotein expression in human breast carcinoma. Cancer Lett. 2003;190(2):191-197.
37. Yang JY, Ha SA, Yang YS, Kim JW. p-Glycoprotein ABCB5 and YB-1 expression plays a role in increased heterogeneity of breast cancer cells: correlations with cell fusion and doxorubicin resistance. BMC Cancer. 2010;10:388.
38. Yasen M, Kajino K, Kano S, Tobita H, Yamamoto J, Uchiumi T, et al. The up-regulation of Y-box binding proteins (DNA binding protein A and Y-box binding protein-1) as prognostic markers of hepatocellular carcinoma. Clin Cancer Res. 2005;11(20):7354-7361.
39. Habibi G, Leung S, Law JH, Gelmon K, Masoudi H, Turbin D, et al. Redefning prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specifc survival than estrogen receptor or HER-2 across all tumor subtypes. Breast Cancer Res. 2008;10(5):R86.
40. Huang J, Tan PH, Li KB, Matsumoto K, Tsujimoto M, Bay BH. Y-box binding protein, YB-1, as a marker of tumor aggressiveness and response to adjuvant chemotherapy in breast cancer. Int J Oncol. 2005;26(3):607-613.
41. Jurchott K, Kuban RJ, Krech T, Bluthgen N, Stein U, Walther W, et al. Identifcation of Y-box binding protein 1 as a core regulator of MEK/ERK pathway-dependent gene signatures in colorectal cancer cells. PLoS Genet. 2010;6(12).
42. To K, Zhao Y, Jiang H, Hu K, Wang M, Wu J, et al. The phos-phoinositide-dependent kinase-1 inhibitor 2-amino-N-[4-[5-(2-phenanthrenyl)-3-(trifuoromethyl)-1H-pyrazol-1-yl]phenyl]-ace tamide (OSU-03012) prevents Y-box binding protein-1 from inducing epidermal growth factor receptor. Mol Pharmacol. 2007;72(3):641-652.
43. Chaudhary PM, Roninson IB. Induction of multidrug resistance in human cells by transient exposure to diferent chemothera-peutic drugs. J Natl Cancer Inst. 1993;85(8):632-639.
44. Gluz O, Mengele K, Schmitt M, Kates R, Diallo-Danebrock R, Nef F, et al. Y-box-binding protein YB-1 identifies high-risk patients with primary breast cancer benefting from rapidly cycled tandem high-dose adjuvant Chemotherapy. J Clin Oncol. 2009;27(36):6144-6151.